Structure - Workplan components
The work plans of the RESCEU project have been developed to support the overall objectives of the project.
| International Scientific Advisory Group | Patient Advisory Board | Ethics Advisory Committee | |||||||||
  | | | |||||||||
 | Project Management & outreach to stakeholders (WP6) |  | |||||||||
| |||||||||||
| Presumed risk factors and biomarkers for RSV-related severe disease and related sequelae (WP5) | | ||||||||||
| |||||||||||
| Prospective data collection (WP4) | | |||||||||
| |||||||||||
| Consolidation of health care systems data (WP2) | | Retrospective resource use analyses from existing databases / networks (WP3) | | |||||||
| | ||||||||||
| Systematic literature review on RSV and current estimates of burden of disease (WP1) | | |||||||||
Among other activities, RESCEU will deliver systematic literature review on RSV disease burden, retrospective data integration and statistical and economic models.
| Global and European RSV disease burden estimates | Reviews of current RSV prevention and treatment guidelines | |||
| | |||
| High-level RSV Science Policy Summit | ||||
| | |||
| RSV data assembly from national routine data and sentinel surveillance systems | RSV economic burden estimates and models to estimate cost effectiveness of RSV interventions | |||
RESCEU will develop a number of prospective clinical studies aimed at addressing the identified gaps and at better understanding the impact of RSV.
| Clinical Study 1: Birth cohort M7-M44 | Clinical Study 2: Infant case-control M7-M44 |
| Clinical Study 3: Older adults >60 M7-M42 | Clinical Study 4: COPD M7-M40 |
Moreover, RESCEU will work on the identification of biomarkers associated with severe RSV infection and sequelae.
| Biomarker Discovery | ||
| Literature review | Case-Control Study | Biobank analysis |
|
||
| Biomarker Validation & fyrther discovery opportunities | ||
| Infant Cohort & Biobank | Elderly Cohort | COPD Cohort |
|
||
| Biomarker for disease, immunity and sequelae | ||